Loss of transforming growth factor-β (TGF-β) receptor type I mediates TGF-β resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression

被引:19
作者
Mi, YD
Borger, DR
Fernandes, PR
Pirisi, L
Creek, KE [1 ]
机构
[1] Univ S Carolina, Dept Pediat, Childrens Canc Res Lab, Columbia, SC 29208 USA
[2] Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA
关键词
D O I
10.1006/viro.2000.0283
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human keratinocytes (HKc) immortalized by human papillomavirus type 16 DNA (HKc/HPV16) progress toward malignancy through growth factor-independent (HKc/GFI) and differentiation-resistant stages (HKc/DR). This progression is associated with a loss of sensitivity to growth inhibition by both all-trans-retinoic acid (RA) and transforming growth factor-beta (TGF-beta). In the accompanying article (Borger et al., 2000, Virology 270, 397-407), we demonstrate that RA resistance in HKc/HPV16 arises despite functional nuclear retinoid receptors and that TGF-beta mediates growth inhibition by RA. To Investigate the basis for the loss of TGF-beta sensitivity during in vitro progression of HKc/HPV16, we explored the expression of TGF-beta receptors type I and type II in independently derived HKc/HPV16 lines and their corresponding HKc/GFI and HKc/DR derivatives. While TGF-P receptor type II mRNA levels were unchanged during progression, mRNA levels for TGF-beta receptor type I decreased dramatically as the cells became TGF-beta resistant. At the HKc/DR stage, loss of TGF-beta receptor type I mRNA, compared to low-passage cells, ranged from 55 to 87% in four HKc/HPV16 lines examined. Immunohistochemistry, using anti-TGF-beta receptor type I antibodies, confirmed a loss of TGF-beta receptor type I expression in HKc/DR. Reintroduction of the TGF-beta-receptor type I into TGF-beta-resistant HKc/DR completely restored growth inhibition by TGF-beta; Southern blot analysis of DNA extracted from normal HKc, HKc/HPV16, and HKc/DR ruled out any gross changes in the TGF-beta receptor type I gene. The activity of the TGF-beta receptor type I promoter, cloned upstream of a luciferase reporter gene, was decreased in HKc/DR, to an extent comparable to the decrease in mRNA levels for the TGF-beta receptor type I. Thus, TGF-beta resistance at late stages of HPV16-mediated transformation of HKc is the result of a loss of expression of TGF-P receptor type I. (C) 2000 Academic Press.
引用
收藏
页码:408 / 416
页数:9
相关论文
共 68 条
[1]   Induction of transforming growth factor-β receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2′-deoxycytidine [J].
Ammanamanchi, S ;
Kim, SJ ;
Sun, LZ ;
Brattain, MG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) :16527-16534
[2]  
ANZANO MA, 1989, CANCER RES, V49, P2898
[3]   TGF-BETA RECEPTORS AND ACTIONS [J].
ATTISANO, L ;
WRANA, JL ;
LOPEZCASILLAS, F ;
MASSAGUE, J .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1994, 1222 (01) :71-80
[4]  
Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO
[5]  
2-B
[6]   THE OCCURRENCE OF EPIDERMAL GROWTH-FACTOR RECEPTORS AND THE CHARACTERIZATION OF EGF-LIKE FACTORS IN HUMAN OVARIAN, ENDOMETRIAL, CERVICAL AND BREAST-CANCER - EGF RECEPTORS AND FACTORS IN GYNECOLOGICAL CARCINOMAS [J].
BAUKNECHT, T ;
KOHLER, M ;
JANZ, I ;
PFLEIDERER, A .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1989, 115 (02) :193-199
[7]   Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: Regulation by TGF-beta [J].
Bloom, BB ;
Humphries, DE ;
Kuang, PP ;
Fine, A ;
Goldstein, RH .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1996, 1312 (03) :243-248
[8]   Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-β [J].
Borger, DR ;
Mi, YD ;
Geslani, G ;
Zyzak, LL ;
Batova, A ;
Engin, TSW ;
Pirisi, L ;
Creek, KE .
VIROLOGY, 2000, 270 (02) :397-407
[9]  
Brattain Michael G., 1996, Current Opinion in Oncology, V8, P49, DOI 10.1097/00001622-199601000-00009
[10]  
Chen TP, 1999, INT J CANCER, V82, P43